Focus is on Argenes’ Anti-FAS IgM Mab.
DSM Biologics and Argenes signed a biopharmaceutical manufacturing agreement. Under the terms of the agreement, DSM Biologics will provide Argenes with full process development services, analytical development services, and manufacturing batches for Argenes’ Anti-Fas IgM Mab.

Argenes’ Anti-FAS IgM Mab is being developed as an antirheumatic agent. The services will be provided out of DSM Biologics’ manufacturing facility in Groningen, The Netherlands.

Previous articleSigma-Aldrich Nabs Advanced Separation Technologies
Next articleAlligator Bioscience and AlgoNomics Ink Therapeutic Protein Partnership